Zenas BioPharma, Inc. - Common Stock (NQ:ZBIO)

26.98 +0.53 (+2.00%)

Streaming Delayed Price Updated: 12:58 PM EDT, Jul 7, 2026 Add to My Watchlist

Price and Volume

Volume	282,515
Open	26.49
Bid (Size)	26.97 (300)
Ask (Size)	27.03 (300)
Prev. Close	26.45
Today's Range	25.88 - 27.18
52wk Range	9.320 - 44.60
Shares Outstanding	41,793,412
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction. ↗

June 21, 2026

This clinical-stage biotech focused on immunology therapies reported a notable insider buy amid a year of strong stock performance.

Via The Motley Fool

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 17, 2026

From Zenas BioPharma

Via GlobeNewswire

Performance

YTD	-21.8%	-21.8%
1 Month	+53.2%	+53.2%
3 Month	+21.2%	+21.2%
6 Month	+62.4%	+62.4%
1 Year	+175.6%	+175.6%

More News

Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

June 11, 2026

From Zenas BioPharma

Via GlobeNewswire

Why Is ZBIO Stock Falling Pre-Market Today? ↗

January 06, 2026

Via Stocktwits

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine

June 02, 2026

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD

May 28, 2026

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress

May 19, 2026

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 18, 2026

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor

May 13, 2026

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 17, 2026

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

March 27, 2026

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock

March 26, 2026

From Zenas BioPharma

Via GlobeNewswire

ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗

March 21, 2026

Via The Motley Fool

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 16, 2026

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 16, 2026

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 20, 2026

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026

February 09, 2026

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

February 04, 2026

From Zenas BioPharma

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO

February 03, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

January 27, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

January 20, 2026

From Pomerantz LLP

Via GlobeNewswire

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026

From Zenas BioPharma

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

January 13, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

January 06, 2026

From Pomerantz LLP

Via GlobeNewswire

Frequently Asked Questions

Is Zenas BioPharma, Inc. - Common Stock publicly traded?

Yes, Zenas BioPharma, Inc. - Common Stock is publicly traded.

What exchange does Zenas BioPharma, Inc. - Common Stock trade on?

Zenas BioPharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Zenas BioPharma, Inc. - Common Stock?

The ticker symbol for Zenas BioPharma, Inc. - Common Stock is ZBIO on the Nasdaq Stock Market

What is the current price of Zenas BioPharma, Inc. - Common Stock?

The current price of Zenas BioPharma, Inc. - Common Stock is 26.98

When was Zenas BioPharma, Inc. - Common Stock last traded?

The last trade of Zenas BioPharma, Inc. - Common Stock was at 07/07/26 12:58 PM ET

What is the market capitalization of Zenas BioPharma, Inc. - Common Stock?

The market capitalization of Zenas BioPharma, Inc. - Common Stock is 1.13B

How many shares of Zenas BioPharma, Inc. - Common Stock are outstanding?

Zenas BioPharma, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.